Novavax reported $126.2M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Adma Biologics USD 64.2M 12.21M Mar/2026
Agenus USD -221.22M 241.03M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Cassava Sciences USD 11.17M 2.38M Mar/2026
Geron USD 52.07M 6.73M Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
MannKind USD 110.9M 8.74M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.78B 242M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
Sanofi EUR 9.31B 1.2B Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
TG Therapeutics USD 170.12M 28.04M Mar/2026